# Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis

> **NCT03517540** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 193 (actual)

## Conditions studied

- Non-alcoholic Steatohepatitis (NASH)

## Interventions

- **DRUG:** Tropifexor (LJN452)
- **DRUG:** Cenicriviroc (CVC)

## Key facts

- **NCT ID:** NCT03517540
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-11
- **Primary completion:** 2020-09-15
- **Final completion:** 2020-10-15
- **Target enrollment:** 193 (ACTUAL)
- **Last updated:** 2022-04-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03517540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03517540, "Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03517540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*